INtraveNous and Oral administration of elinogrel to eVAluate Tolerability and Efficacy in nonurgent PCI patients - INNOVATE PCI

Description:

The goal of the trial was to evaluate treatment with the intravenous (IV) and oral P2Y12 receptor inhibitor (elinogrel) compared with clopidogrel during nonurgent percutaneous coronary intervention (PCI). Elinogrel is a direct acting reversible agent, which competitively binds to the P2Y12 receptor. This is a phase 2b dose-finding study for elinogrel.